LIVMARLI, the only IBAT inhibitor available in both an oral solution and tablet formulation options, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. for cholestatic pruritus in PFIC patients (twelve months and older) and in Europe (three months and older). Mirum has initiated the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. 

CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease.

CTEXLI is the first and only FDA approved treatment for cerebrotendinous xanthomatosis (CTX).